Biogen stock jumped early Wednesday after the biotech company reported adjusted income of $4.77 per share on $2.78 billion in third-quarter sales.
On average, analysts polled by FactSet expected Biogen (BIIB) to earn $4.11 per share on $2.67 billion in sales.
Biogen also reported $300,000 in sales of its new Alzheimer's drug, Aduhelm. Chief Executive Michel Vounatsos said uptake is delayed "but we continue to believe in its long-term potential."
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,